{"id":3025,"date":"2025-11-10T16:44:21","date_gmt":"2025-11-10T16:44:21","guid":{"rendered":"https:\/\/www.biogenera.com\/?p=3025"},"modified":"2026-05-27T11:06:32","modified_gmt":"2026-05-27T11:06:32","slug":"biogenera-aggiornamento-sui-progressi-verso-la-fase-clinica-di-bga002-e-lo-sviluppo-della-pipeline","status":"publish","type":"post","link":"https:\/\/www.biogenera.com\/en\/biogenera-aggiornamento-sui-progressi-verso-la-fase-clinica-di-bga002-e-lo-sviluppo-della-pipeline\/","title":{"rendered":"Biogenera: Update on Progress Toward the Clinical Phase of BGA002 and Pipeline Development"},"content":{"rendered":"<p class=\"gmail_default translation-block\" dir=\"ltr\">Throughout 2025, Biogenera S.p.A. has continued to make significant progress in advancing its lead drug candidate, BGA002, and expanding its pipeline based on Peptide Nucleic Acid (PNA) technology, while strengthening both scientific and industrial collaborations on a global scale.<\/p>\n<p>&nbsp;<\/p>\n<div style=\"padding: 56.25% 0 0 0; position: relative;\"><iframe style=\"position: absolute; top: 0; left: 0; width: 100%; height: 100%;\" title=\"Biogenera: Update on Progress Toward the Clinical Phase of BGA002 and Pipeline Development\" src=\"https:\/\/player.vimeo.com\/video\/1135448614?title=0&amp;byline=0&amp;portrait=0&amp;badge=0&amp;autopause=0&amp;player_id=0&amp;app_id=58479\" frameborder=\"0\"><\/iframe><\/div>\n<p><script src=\"https:\/\/player.vimeo.com\/api\/player.js\"><\/script><\/p>\n<h3 class=\"gmail_default\" dir=\"ltr\">BGA002: From Research to Clinical Development<\/h3>\n<p class=\"gmail_default translation-block\" dir=\"ltr\">The GMP (Good Manufacturing Practice) production process of the Active Pharmaceutical Ingredient (API) of BGA002 has been successfully completed \u2014 a historic milestone marking the first large-scale GMP-compliant production of a PNA-based molecule.\nThis achievement represents a crucial step toward the clinical phase of the drug, developed for the treatment of aggressive pediatric cancers associated with the MYCN gene.<\/p>\n<p class=\"gmail_default translation-block\" dir=\"ltr\">The next step will be the fill &amp; finish phase, consisting of sterile vial filling, expected to be completed by the end of 2025.\nIn parallel, Biogenera\u2019s regulatory team is finalizing the necessary procedures for the initiation of the Phase I clinical trial, scheduled to begin in early 2026, which will involve a population of pediatric patients.<\/p>\n<h3 dir=\"ltr\"><\/h3>\n<h3 class=\"gmail_default\" dir=\"ltr\">Expanding Orphan Drug Designations<\/h3>\n<p class=\"gmail_default translation-block\" dir=\"ltr\">BGA002 has already received Orphan Drug Designation from both the EMA and the FDA for Neuroblastoma and Rhabdomyosarcoma.\nFurther efforts are underway to extend the designation to additional oncological indications, with the goal of broadening the therapeutic potential of the drug and consolidating the company\u2019s leadership in the field of rare pediatric and other severe diseases.<\/p>\n<h3 dir=\"ltr\"><\/h3>\n<h3 class=\"gmail_default\" dir=\"ltr\">Scientific Collaborations and International Development<\/h3>\n<p class=\"gmail_default translation-block\" dir=\"ltr\">Biogenera continues to strengthen collaborations with leading research institutions worldwide. Among these, the University of Chicago, where joint preclinical studies are underway to evaluate the efficacy and mechanism of action of BGA002.\nResearch activities also extend to new therapeutic areas in adult oncology, including Small Cell Lung Cancer (SCLC), for which additional preclinical developments are planned.<\/p>\n<h3 dir=\"ltr\"><\/h3>\n<h3 class=\"gmail_default\" dir=\"ltr\">Pipeline and New Areas of Innovation<\/h3>\n<p class=\"gmail_default translation-block\" dir=\"ltr\">Beyond BGA002, Biogenera is advancing a diversified pipeline of drug candidates, including BGA003 in oncology and another research program in dermatology.\nAt the same time, the company is developing the new \u201cLongevity Initiative,\u201d which aims to apply PNA technology to the field of longevity and aging medicine, with potential therapeutic and diagnostic applications.<\/p>\n<h3 dir=\"ltr\"><\/h3>\n<h3 class=\"gmail_default\" dir=\"ltr\">Industrial and Financial Outlook<\/h3>\n<p class=\"gmail_default translation-block\" dir=\"ltr\">On the corporate side, Biogenera continues to engage in active discussions with potential international partners interested in the commercial development of BGA002 and in enhancing the value of PNA technology.\nA new fundraising round is also being prepared to support clinical development and to internalize the GMP manufacturing of PNA for clinical use \u2014 a strategic capability that represents one of the company\u2019s most valuable assets and could serve as a future source of additional revenue streams.<\/p>\n<div>\n<div class=\"adm\">\n<div id=\"q_9\" class=\"ajR h4\" data-tooltip=\"Hide expanded content\" aria-label=\"Hide expanded content\" aria-expanded=\"true\">\n<div class=\"ajT\"><\/div>\n<\/div>\n<\/div>\n<div class=\"im\">\n<h3 class=\"gmail_default\" dir=\"ltr\">Looking Ahead<\/h3>\n<p class=\"gmail_default translation-block\" dir=\"ltr\">Biogenera remains firmly committed to its mission: bringing new therapeutic options to children and adults affected by aggressive cancers, where treatment alternatives remain limited.\nEach step forward brings the company closer to its goal \u2014 transforming scientific research into tangible solutions for patients.<\/p>\n<p class=\"gmail_default translation-block\" dir=\"ltr\">In the coming months, Biogenera will explore each of these topics in greater detail through dedicated articles, offering deeper insight into the scientific, industrial, and human journey that drives our vision.<\/p>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Nel corso del 2025,\u00a0Biogenera S.p.A.\u00a0ha continuato a compiere passi decisivi nello sviluppo del proprio farmaco pi\u00f9 avanzato,\u00a0BGA002, e nell\u2019espansione della propria\u00a0pipeline\u00a0basata su tecnologia\u00a0PNA (Peptide Nucleic Acid), rafforzando al tempo stesso collaborazioni scientifiche e industriali a livello internazionale. &nbsp; BGA002: dalla ricerca alla clinica \u00c8 stato completato con successo il processo di\u00a0produzione GMP (Good Manufacturing Practice)\u00a0del\u00a0principio attivo (API)\u00a0di BGA002 \u2014 un traguardo storico che segna la\u00a0prima produzione su larga scala di un PNA conforme agli standard GMP. Questo risultato rappresenta un passaggio fondamentale per l\u2019avvio della fase clinica del farmaco, sviluppato per il trattamento di\u00a0tumori pediatrici aggressivi\u00a0associati al gene\u00a0MYCN. Il prossimo step sar\u00e0 il\u00a0fill &amp; finish, ovvero l\u2019infialamento in condizioni sterili,\u00a0previsto entro la fine del 2025. Parallelamente, il team regolatorio di Biogenera sta completando le procedure necessarie per l\u2019avvio dello\u00a0studio clinico di Fase I, previsto per l\u2019inizio del\u00a02026, che coinvolger\u00e0 una popolazione di pazienti pediatrici. Espansione delle designazioni Orphan Drug BGA002 ha gi\u00e0 ottenuto la\u00a0designazione di farmaco orfano (Orphan Drug Designation)\u00a0da parte di\u00a0EMA\u00a0e\u00a0FDA\u00a0per il\u00a0Neuroblastoma\u00a0e il\u00a0Rhabdomyosarcoma. Sono inoltre in corso attivit\u00e0 per\u00a0estendere la designazione ad altre indicazioni oncologiche, con l\u2019obiettivo di ampliare l\u2019impatto terapeutico del farmaco e consolidare la leadership dell\u2019azienda nell\u2019ambito delle\u00a0malattie rare pediatriche\u00a0e non solo. Collaborazioni scientifiche e sviluppo internazionale Proseguono le collaborazioni di Biogenera con\u00a0istituzioni di ricerca di eccellenza\u00a0a livello globale. Tra queste, la\u00a0University of Chicago, dove sono in corso\u00a0studi preclinici congiunti\u00a0per valutare l\u2019efficacia e i meccanismi d\u2019azione di BGA002. Le attivit\u00e0 di ricerca si estendono inoltre a\u00a0nuove aree terapeutiche\u00a0in oncologia dell\u2019adulto, tra cui il\u00a0carcinoma polmonare a piccole cellule (SCLC), per il quale sono previsti ulteriori sviluppi preclinici. Pipeline e nuove aree di innovazione Oltre a BGA002, Biogenera sta portando avanti una\u00a0pipeline diversificata\u00a0di candidati farmaci, tra cui\u00a0BGA003\u00a0nell\u2019ambito oncologico e un ulteriore programma di ricerca in\u00a0dermatologia. Parallelamente, \u00e8 in fase di sviluppo la nuova\u00a0\u201cLongevity Initiative\u201d, che punta ad applicare la tecnologia PNA anche alla\u00a0medicina della longevit\u00e0 e dell\u2019invecchiamento, con potenziali applicazioni terapeutiche e diagnostiche. Prospettive industriali e finanziarie Sul fronte corporate, Biogenera continua a tenere attivi i dialoghi con potenziali partner\u00a0internazionali interessati ad uno sviluppo commerciale del BGA002 volti a alla valorizzazione della tecnologia PNA. \u00c8 inoltre in preparazione una\u00a0nuova fase di raccolta fondi, destinata a\u00a0sostenere lo sviluppo clinico\u00a0e ad internalizzare la\u00a0produzione di PNA in GMP\u00a0da usarsi durante gli sviluppi clinici \u2014\u00a0una competenza strategica che rappresenta oggi uno degli asset pi\u00f9 rilevanti dell\u2019azienda e che potr\u00e0 contribuire in futuro alla generazione di\u00a0nuove linee di ricavo. Uno sguardo al futuro Biogenera prosegue con determinazione nella propria missione:\u00a0portare nuove opzioni terapeutiche ai bambini e agli adulti affetti da tumori aggressivi, dove oggi le alternative sono limitate. Ogni progresso avvicina l\u2019azienda al suo obiettivo: trasformare la ricerca scientifica in soluzioni concrete per i pazienti. Nei prossimi mesi, Biogenera approfondir\u00e0 ciascuna di queste tematiche con\u00a0articoli dedicati, per raccontare nel dettaglio il percorso scientifico, industriale e umano che guida la nostra visione.<\/p>","protected":false},"author":1,"featured_media":3127,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"footnotes":""},"categories":[5,3],"tags":[],"class_list":["post-3025","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-aggiornamento-societario","category-news"],"_links":{"self":[{"href":"https:\/\/www.biogenera.com\/en\/wp-json\/wp\/v2\/posts\/3025","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.biogenera.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.biogenera.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.biogenera.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.biogenera.com\/en\/wp-json\/wp\/v2\/comments?post=3025"}],"version-history":[{"count":4,"href":"https:\/\/www.biogenera.com\/en\/wp-json\/wp\/v2\/posts\/3025\/revisions"}],"predecessor-version":[{"id":3128,"href":"https:\/\/www.biogenera.com\/en\/wp-json\/wp\/v2\/posts\/3025\/revisions\/3128"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.biogenera.com\/en\/wp-json\/wp\/v2\/media\/3127"}],"wp:attachment":[{"href":"https:\/\/www.biogenera.com\/en\/wp-json\/wp\/v2\/media?parent=3025"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.biogenera.com\/en\/wp-json\/wp\/v2\/categories?post=3025"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.biogenera.com\/en\/wp-json\/wp\/v2\/tags?post=3025"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}